Sylvester Comprehensive Cancer Center

  • ADVL1622 - Barredo, Julio

  • Investigator:
    Julio Barredo
    RCname Email

    		Coordinator:
    RCemailImg Wendy Best
    RCphone 3052430844

    IRB: 20170579

    		SDG: Pediatric Cancer
    Disease Site(s):

    Kidney,Bones and Joints,Soft Tissue
    Sponsor: COG

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with refractory Sarcomas, Wilms Tumor, and Other Rare Tumors.
    Eligibility Criteria - NCT02867592 *This information has been extracted from " www.clinicaltrials.gov"

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20170529

    		SDG: Breast Cancer
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma,Multiple
    Sponsor: ASCO

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • VYR-VSV2-101 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Reisy Guedes
    RCphone 3052438807

    IRB: 20170023

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Lung,Melanoma, skin,Kaposis sarcoma
    Sponsor: VYRIAD

    Enrolling Sites:

    Sylvester
    Title:

    Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human interferon beta (VSV-IFNß-NIS), in Patients with Refractory Solid Tumors
    Eligibility Criteria - NCT02923466 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC- 096 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    		Coordinator:
    RCemailImg Dilanis Perche
    RCphone 3052438373

    IRB: 20180804

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Kaposis sarcoma
    Sponsor: AMC

    Enrolling Sites:

    Sylvester
    Title:

    AMC-096: A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
    Eligibility Criteria - NCT02799485 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC 098 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    		Coordinator:
    RCemailImg Dilanis Perche
    RCphone 3052438373

    IRB: 20180856

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Kaposis sarcoma
    Sponsor: AMC

    Enrolling Sites:

    Sylvester
    Title:

    AMC-098:A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
    Eligibility Criteria - NCT03077451 *This information has been extracted from " www.clinicaltrials.gov"

  • CITN-13 - Schatz, Jonathan

  • Investigator:
    Jonathan Schatz
    RCname Email

    		Coordinator:
    RCemailImg Dilanis Perche
    RCphone 3052438373

    IRB: 20180920

    		SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Mycosis Fungoides
    Sponsor: Cancer Immunotherapy Trials Network

    Enrolling Sites:

    Sylvester
    Title:

    CITN-13 :A Phase II Trial Of MK-3475 (Pembrolizumab) And Interferon Gamma 1-B Combination Immunotherapy In Patients With Previously Treated Mycosis Fungoides And Sézary Syndrome (Treatment Group 1) And In Patients With Advanced Synovial Sarcoma (Treatment Group 2)
    Eligibility Criteria - NCT03063632 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20150671

    		SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma
    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    Title:

    Molecular Analysis for Therapy Choice (MATCH)
    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • Anlotinib AL3818-US-004A - Trent, Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:
    RCemailImg Lizbeth Bornote
    RCphone 3052436817

    IRB: 20170072

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Soft Tissue
    Sponsor: ADVENCHEN LABORATORIES

    Enrolling Sites:

    Sylvester
    Title:

    AL3818-US-004A: Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
    Eligibility Criteria - NCT03016819 *This information has been extracted from " www.clinicaltrials.gov"